Modern approach to pharmacotherapy of chronic insomnia in childhood

Abstract

Insomnia is a widespread problem in the pediatric population. The prevalence of insomnia in childhood varies from 5% to 50%. The lack of adequate therapy can lead to chronicity, impairment of cognitive and motor functions, and eventually development of cardiovascular and metabolic diseases, diabetes, and gastrointestinal and mental disorders. Thus, timely identification and treatment of childhood insomnia is important. This study aimed to summarize and systematize current information about the modern approach to pharmacotherapy of chronic insomnia in childhood. Modern and foreign randomized controlled trials over the past 10 years were analyzed. Treatment of chronic insomnia includes non-pharmacological and pharmacological approaches. Behavioral strategies are recommended as first-line treatment for childhood insomnia. The availability of different pharmacological drug groups allows for a personalized approach to treatment. However, the use of off-label drugs requires a justified prescription. The lack of large-scale clinical studies on the effectiveness, tolerability, dosing, and safety profile of drugs implies the need for further research to better understand the risks (negative side effects) and benefits of using such drugs for treating sleep disorders in children.

Keywords

insomnia / nootropics / melatonin / antidepressants / anxiolytics / neuroleptics / antihistamines / anticonvulsants

References

[1] Al Lihabi A. A literature review of sleep problems and neurodevelopment disorders. Front Psychiatry. 2023;14:1122344. doi: 10.3389/fpsyt.2023.1122344

[2] Al Lihabi A. A literature review of sleep problems and neurodevelopment disorders // Front Psychiatry. 2023. Vol. 14. ID 1122344. doi: 10.3389/fpsyt.2023.1122344

[3] Coogan AN, Baird AL, Popa-Wagner A, Thome J. Circadian rhythms and attention defcit hyperactivity disorder: the what, the when and the why. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;67:74–81. doi: 10.1016/j.pnpbp.2016.01.006

[4] Coogan A.N., Baird A.L., Popa-Wagner A., Thome J. Circadian rhythms and attention defcit hyperactivity disorder: the what, the when and the why // Prog Neuro-Psychopharmacol Biol Psychiatry. 2016. Vol. 67. P. 74–81. doi: 10.1016/j.pnpbp.2016.01.006

[5] Chokroverty S. Overview of sleep and sleep disorders. Indian J Med Res. 2010;131:126–140.

[6] Chokroverty S. Overview of sleep and sleep disorders // Indian J Med Res. 2010. Vol. 131. P. 126–140.

[7] Ogundele MO, Yemula C. Management of sleep disorders among children and adolescents with neurodevelopmental disorders: A practical guide for clinicians. World J Clin Pediatr. 2022;11(3): 239–252. doi: 10.5409/wjcp.v11.i3.239

[8] Ogundele M.O., Yemula C. Management of sleep disorders among children and adolescents with neurodevelopmental disorders: A practical guide for clinicians // World J Clin Pediatr. 2022. Vol. 11, N 3. P. 239–252. doi: 10.5409/wjcp.v11.i3.239

[9] Gregory AM, Sadeh A. Sleep, emotional and behavioral difficulties in children and adolescents. Sleep Med Rev. 2012;16(2):129–136. doi: 10.1016/j.smrv.2011.03.007

[10] Gregory A.M., Sadeh A. Sleep, emotional and behavioral diffculties in children and adolescents // Sleep Med Rev. 2012. Vol. 16, N 2. P. 129–136. doi: 10.1016/j.smrv.2011.03.007

[11] Irwin MR. Why sleep is important for health: A psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143–172. doi: 10.1146/annurev-psych-010213-115205

[12] Irwin M.R. Why sleep is important for health: A psychoneuroimmunology perspective // Annu Rev Psychol. 2015. Vol. 66. P. 143–172. doi: 10.1146/annurev-psych-010213-115205

[13] Karabanova OА. In search of an optimal parenting style. National Psychological Journal. 2019;3(3):71–79. EDN: WFULTG doi: 10.11621/npj.2019.0308

[14] Карабанова О.А. В поисках оптимального стиля родительского воспитания // Национальный психологический журнал. 2019. Т. 3, № 3. С. 71–79. EDN: WFULTG doi: 10.11621/npj.2019.0308

[15] Poluektov MG. Sleep disorders in childhood: causes and modern therapy. Effective pharmacotherapy. 2012;(1):32–39. EDN: SLUCSZ (In Russ.)

[16] Полуэктов М.Г. Нарушения сна в детском возрасте: причины и современна терапия // Эффективная фармакотерапия. 2012. № 1. C. 32–39. EDN: SLUCSZ

[17] Kharlamov DA, Kremenchugskaya MR, Trifonova OE. Polysomnography in the sleep disorders diagnostics in children. Russian Bulletin of Perinatology and Pediatrics. 2008;53(5):52–58. EDN: JUAQSV

[18] Харламов Д.А., Кременчугская М.Р., Трифонова О.А. Полисомнография в диагностике нарушений сна у детей // Российский вестник перинатологии и педиатрии. 2008. Т. 53, № 5. С. 52–58. EDN: JUAQSV

[19] American Academy of Sleep Medicine. International classification of sleep disorders. 3rded. (ICSD-3). Darien: American Academy of Sleep Medicine; 2014.

[20] Американская академия медицины сна. Международная классификация нарушений сна. 3-е изд. (ICSD-3). Дариен: Американская академия медицины сна, 2014.

[21] Maski K, Owens JF. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management. Lancet Neurol. 2016;15(11):1170–1181. doi: 10.1016/S1474-4422(16)30204-6

[22] Maski K., Owens J.F. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management // Lancet Neurol. 2016. Vol. 15, N 11. P. 1170–1181. doi: 10.1016/S1474-4422(16)30204-6

[23] Korabelnikova EA. Treatment and prevention of insomnia in infants and young children. Russian Journal of Psychiatry. 2012;(3):62–67. EDN: PBYNTH

[24] Корабельникова Е.А. Лечение и профилактика инсомний у детей раннего возраста // Российский психиатрический журнал. 2012. № 3. С. 62–67. EDN: PBYNTH

[25] BruniО, Angriman M, Calisti F, et al. Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatry. 2018;59(5): 489–508. doi: 10.1111/jcpp.12812

[26] Bruni О., Angriman M., Calisti F., et al. Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities // J Child Psychol Psychiatry.2018. Vol. 59, N 5. P. 489–508. doi: 10.1111/jcpp.12812

[27] Zhou ES, Owens J. Behavioral treatments for pediatric insomnia. Curr Sleep Med Rep. 2016;2:127–135. doi: 10.1007/s40675-016-0053-0

[28] Zhou E.S., Owens J. Behavioral treatments for pediatric insomnia // Curr Sleep Med Rep. 2016. Vol. 2. P. 127–135. doi: 10.1007/s40675-016-0053-0

[29] Kang EK, Kim SS. Behavioral insomnia in infants and young children. Clin Exp Pediatr. 2021;64(3):111–116. doi: 10.3345/cep.2020.00052

[30] Kang E.K., Kim S.S. Behavioral insomnia in infants and young children // Clin Exp Pediatr. 2021. Vol. 64, N 3. P. 111–116. doi: 10.3345/cep.2020.00052

[31] Pchelina PV, Poluektov MG. How to treat insomnia of early childhood. Effective pharmacotherapy. 2016;(19):52–58. EDN: WIEOWT

[32] Пчелина П.В., Полуэктов М.Г. Как лечить инсомнию раннего детского возраста // Эффективная фармакотерапия. 2016. Т. 19. С. 52–58. EDN: WIEOWT

[33] Narasimhan U, Anitha FS, Battula M Jr. Specific learning disability unmasked by psychophysiological insomnia. Cureus. 2020;12(3): e7480. doi: 10.7759/cureus.7480

[34] Narasimhan U., Anitha F.S., Battula M. Jr. Specific learning disability unmasked by psychophysiological insomnia // Cureus. 2020. Vol. 12, N 3. ID e7480. doi:10.7759/cureus.7480

[35] Ophof D, Slaats MA, Boudewyns A, et al. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018;177(5):641–648. doi: 10.1007/s00431-018-3116-z

[36] Ophof D., Slaats M.A., Boudewyns A., et al. Sleep disorders during childhood: a practical review //Eur J Pediatr. 2018. Vol. 177, N 5. P. 641–648. doi: 10.1007/s00431-018-3116-z

[37] Kaczor M, Skalski M. Treatment of behavioral sleep problems in children and adolescents — literature review. Psychiatr Pol. 2016;50(3):571–584. doi: 10.12740/PP/41294

[38] Kaczor M., Skalski M. Treatment of behavioral sleep problems in children and adolescents — literature review // Psychiatr Pol. 2016. Vol. 50, N 3. P. 571–584. doi: 10.12740/PP/41294

[39] Neubauer DN, Pandi-Perumal SR, Spence DW, et al. Pharmacotherapy of Insomnia. J Cent Nerv Syst Dis. 2018;10:1179573518770672. doi: 10.1177/1179573518770672

[40] Neubauer D.N., Pandi-Perumal S.R., Spence D.W., et al. Pharmacotherapy of Insomnia // J Cent NervSyst Dis. 2018. Vol. 10. ID 1179573518770672. doi: 10.1177/1179573518770672

[41] Okovityi SV, Titovich IA. Pharmacotherapy treatment principles for insomnia. Medical council. 2018;(6):26–32. EDN: YVEXRJ doi: 10.21518/2079-701X-2018-6-26-32

[42] Оковитый С.В., Титович И.А. Фармакологические принципы терапии инсомнии // Медицинский совет. 2018. № 6. С. 26–32. EDN: YVEXRJ doi: 10.21518/2079-701X-2018-6-26-32

[43] Monti JM. The neurotransmitters of sleep and wake, a physiological reviews series. Sleep Med Rev. 2013;17(4):313–315. doi: 10.1016/j.smrv.2013.02.004

[44] Monti J.M. The neurotransmitters of sleep and wake, a physiological reviews series // Sleep Med Rev. 2013. Vol. 17, N 4. P. 313–315. doi: 10.1016/j.smrv.2013.02.004

[45] Pelayo R, Dubic M. Pediatric sleep pharmacology. Semin Pediatr Neurol. 2008;15(2):79–90. doi: 10.1016/j.spen.2008.03.004

[46] Pelayo R., Dubic M. Pediatric sleep pharmacology // Semin Pediatr Neurol. 2008. Vol. 15, N 2. P. 79–90. doi: 10.1016/j.spen.2008.03.004

[47] Monczor F, Fernandez N. Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands. Mol Pharmacol. 2016;90(5):640–648. doi: 10.1124/mol.116.105981

[48] Monczor F., Fernandez N. Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands // Mol Pharmacol. 2016. Vol. 90, N 5. P. 640–648. doi: 10.1124/mol.116.105981

[49] Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005;1(1):49–59. doi: 10.5664/jcsm.26297

[50] Owens J.A., Babcock D., Blumer J., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary // J Clin Sleep Med. 2005. Vol. 1, N 1. P. 49–59. doi: 10.5664/jcsm.26297

[51] Romanov DV, Iuzbashian PG. Acute insomnia: experience of treatment with doxylamine. Medical Council. 2020;(21):267–273. EDN: YZBJOA doi: 10.21518/2079-701X-2020-21-267-273

[52] Романов Д.В., Юзбашян П.Г. Острая инсомния: опыт применения доксиламина // Медицинский совет. 2020. № 21. С. 267–273. EDN: YZBJOA. doi: 10.21518/2079-701X-2020-21-267-273

[53] Samanta S. Physiological and pharmacological perspectives of melatonin. Arch Physiol Biochem. 2022;128(5):1346–1367. doi: 10.1080/13813455.2020.1770799

[54] Samanta S. Physiological and pharmacological perspectives of melatonin // Arch Physiol Biochem. 2022. Vol. 128, N 5. P. 1346–1367. doi: 10.1080/13813455.2020.1770799

[55] Eckerberg B, Lowden A, Nagai R, Åkerstedt T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012;29(9): 1239–1248. doi: 10.3109/07420528.2012.719962;

[56] Eckerberg B., Lowden A., Nagai R., Åkerstedt T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study // Chronobiol Int. 2012. Vol. 29, N 9. P. 1239–1248. doi: 10.3109/07420528.2012.719962;

[57] Van Maanen A, Meijer AM, Smits MG, et al. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017;40(2):zsw038. doi: 10.1093/sleep/zsw038

[58] Van Maanen A., Meijer A.M., Smits M.G., et al. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study // Sleep. 2017. Vol. 40, N 2. ID zsw038. doi: 10.1093/sleep/zsw038

[59] Kryger MH, Roth T, Goldstein CA. Kryger’s principles and practice of sleep medicine. Elsevier Health Sciences; 2021. 2240 p.

[60] Kryger M.H., Roth T., Goldstein C.A. Kryger’s principles and practice of sleep medicine. Elsevier Health Sciences, 2021. 2240 p.

[61] Wagner ML, Walters AS, Fisher BC. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep. 2004;27(8):1499–1504. doi: 10.1093/sleep/27.8.1499

[62] Wagner M.L., Walters A.S., Fisher B.C. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome // Sleep.2004. Vol. 27, N 8. P. 1499–1504. doi: 10.1093/sleep/27.8.1499

[63] Himelfarb M, Shatkin JP. Pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2021;30(1):117–129. doi: 10.1016/j.chc.2020.08.004

[64] Himelfarb M., Shatkin J.P. Pediatric insomnia // Child Adolesc Psychiatr Clin N Am. 2021. Vol. 30, N 1. P. 117–129. doi: 10.1016/j.chc.2020.08.004

[65] Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61(3):383–410. doi: 10.1016/S1734-1140(09)70081-7

[66] Zawilska J.B., Skene D.J., Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms // Pharmacol Rep. 2009. Vol. 61, N 3. P. 383–410. doi: 10.1016/S1734-1140(09)70081-7

[67] Andersen IM, Kaczmarska JA, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23(5):482–485. doi: 10.1177/0883073807309783

[68] Andersen I.M., Kaczmarska J.A., McGrew S.G., Malow B.A. Melatonin for insomnia in children with autism spectrum disorders // J Child Neurol. 2008. Vol. 23, N 5. P. 482–485. doi: 10.1177/0883073807309783

[69] Carr R, Wasdell MB, Hamilton D, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43(4):351–359. doi: 10.1111/j.1600-079X.2007.00485.x

[70] Carr R., Wasdell M.B., Hamilton D., et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders // J Pineal Res. 2007. Vol. 43, N 4. P. 351–359. doi: 10.1111/j.1600-079X.2007.00485.x

[71] Lin G-J, Huang S-H, Chen S-J, et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013;14(6):11742–11766. doi: 10.3390/ijms140611742

[72] Lin G.-J., Huang S.-H., Chen S.-J., et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases // Int J Mol Sci. 2013. Vol. 14, N 6. P. 11742–11766. doi: 10.3390/ijms140611742

[73] Chua HM, Hauet Richer N, Swedrowska M, et al. Dissolution of intact, divided and crushed circadin tablets: prolonged vs. immediate release of melatonin. Pharmaceutics. 2016;8(1):2. doi: 10.3390/pharmaceutics8010002

[74] Chua H.M., Hauet Richer N., Swedrowska M., et al. Dissolution of intact, divided and crushed circadin tablets: prolonged vs. immediate release of melatonin // Pharmaceutics. 2016. Vol. 8, N 1. ID 2. doi: 10.3390/pharmaceutics8010002

[75] Barylnik YB, Filippova NV, Treiber LV. Modern approaches to synchronisation of circadian rhythms in depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11):124–128. EDN: RILCEV (In Russ.)

[76] Барыльник Ю.Б., Филиппова Н.В., Трайбер Л.В. Современные подходы к синхронизации циркадианных ритмов при депрессии // Журнал неврологии и психиатрии им. С.С. Корсакова. 2014. Т. 114, № 11. С. 124–128. EDN: RILCEV

[77] grls.rosminzdrav.ru [Internet]. State register of medicines. Available from: http://grls.rosminzdrav.ru (In Russ.)

[78] grls.rosminzdrav.ru [Электронный ресурс]. Государственный реестр лекарственных средств. Режим доступа: http://grls.rosminzdrav.ru

[79] Pushkarev DF. Alimemazine in psychiatric practice and general medicine (literature review). Mental Disorders in General Medicine. 2013;(1):56–61. EDN: QCALFZ (In Russ.)

[80] Пушкарев Д.Ф. Алимемазин в психиатрической практике и общей медицине (обзор литературы) // Психические расстройства в общей медицине. 2013. № 1. С. 56–61. EDN: QCALFZ

[81] Ramchandani P, Wiggs L, Webb V, Stores G. A systematic review of treatments for settling problems and night waking in young children. BMJ. 2000;320(7229):209–213. doi: 10.1136/bmj.320.7229.209

[82] Ramchandani P., Wiggs L., Webb V., Stores G. A systematic review of treatments for settling problems and night waking in young children // BMJ. 2000. Vol. 320, N 7229. Р. 209–213. doi: 10.1136/bmj.320.7229.209

[83] Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders. Eur Child Adolesc Psychiatry. 2005;14:34–40. doi: 10.1007/s00787-005-0424-4

[84] Ingrassia A., Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders // Eur Child Adolesc Psychiatry. 2005. Vol. 14. P. 34–40. doi: 10.1007/s00787-005-0424-4

[85] Romanov DV, Samsonova MD, Iuzbashian PG. Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123 (4–2):81–89. EDN: TRIOHE doi: 10.17116/jnevro202312304281

[86] Романов Д.В., Самсонова М.Д., Юзбашян П.Г. Терапия психических расстройств, обусловленных либо провоцированных соматической и неврологической патологией, с применением мультимодального антидепрессанта тразодон // Журнал неврологии и психиатрии им. С.С. Корсакова. 2023. Т. 123, № 4–2. С. 81–89. EDN: TRIOHE doi: 10.17116/jnevro202312304281

[87] Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18(36):5802–5817. doi: 10.2174/138161212803523608

[88] Wichniak A., Wierzbicka A., Jernajczyk W. Sleep and antidepressant treatment // Curr Pharm Des. 2012. Vol. 18, N 36. P. 5802–5817. doi: 10.2174/138161212803523608

[89] Belli A, Breda M, Di Maggio C, et al. Children with neurodevelopmental disorders: how do they sleep? // Curr Opin Psychiatry. 2022:1(5):345–351. doi: 10.1097/YCO.0000000000000790. Epub 2022 Feb 15. PMID: 35165244.

[90] Belli A., Breda M., Di Maggio C., et al. Children with neurodevelopmental disorders: how do they sleep? // Curr Opin Psychiatry. 2022. Vol. 1, N 5. P. 345–351. doi: 10.1097/YCO.0000000000000790. Epub 2022 Feb 15. PMID: 35165244.

[91] Khachatrian LG, Pogorelova MS, Geppe NA, et al. The problem of insomnia in infant/young children: issues of diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7–2): 25–32. EDN: CFBLIZ doi: 10.17116/jnevro201911907225

[92] Хачатрян Л.Г., Погорелова М.С., Геппе Н.А., и др. Проблемы нарушения сна у детей раннего возраста: вопросы диагностики и коррекции // Журнал неврологии и психиатрии им. С.С. Корсакова. 2019. Т. 119, № 7–2. С. 25–32. EDN: CFBLIZ doi: 10.17116/jnevro201911907225

[93] Poluéktov MG, Tsenteradze SL. A contemporary conception of insomnia syndrome and its treatments in view of international classification of sleep disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11):92–97. EDN: TGMIDL

[94] Полуэктов М.Г., Центерадзе C.Л. Современные представления о синдроме инсомнии с учетом требований Международной классификации расстройств сна и подходы к ее лечению // Журнал неврологии и психиатрии им. С.С. Корсакова. 2014. Т. 114, № 11. С. 92–97. EDN: TGMIDL

[95] Raggi A, Mogavero MP, DelRosso LM, Ferri R. Clonazepam for the management of sleep disorders. Neurol Sci. 2023;44(1):115–128. doi: 10.1007/s10072-022-06397-x

[96] Raggi A., Mogavero M.P., Del Rosso L.M., Ferri R. Clonazepam for the management of sleep disorders // Neurol Sci. 2023. Vol. 44, N 1. P. 115–128. doi: 10.1007/s10072-022-06397-x

[97] Relia S, Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: A Literature review. Med Sci. 2018;6(4):95. doi: 10.3390/medsci6040095

[98] Relia S., Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: A literature review // Med Sci. 2018. Vol. 6, N 4. ID 95. doi: 10.3390/medsci6040095

[99] Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11(7):692–700. doi: 10.1016/j.sleep.2009.11.015

[100] Owens J.A., Rosen C.L., Mindell J.A., Kirchner H.L. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey // Sleep Med. 2010. Vol. 11, N 7. P. 692–700. doi: 10.1016/j.sleep.2009.11.015

[101] Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. Res Dev Disabil. 2011;32(3):939–962. doi: 10.1016/j.ridd.2010.12.035

[102] Hollway J.A., Aman M.G. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature // Res Dev Disabil. 2011. Vol. 32, N 3. P. 939–962. doi: 10.1016/j.ridd.2010.12.035

[103] Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013;28(12): 1618–1621. doi: 10.1177/0883073812463069

[104] Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013. Vol. 28, N 12. P. 1618–1621. doi: 10.1177/0883073812463069

[105] Meltzer LJ, Mindell JA, Owens JA, Byars KC. Use of sleep medications in hospitalized pediatric patients. Pediatrics. 2007;119(6): 1047–1055. doi: 10.1542/peds.2006-2773

[106] Meltzer L.J., Mindell J.A., Owens J.A., Byars K.C. Use of sleep medications in hospitalized pediatric patients // Pediatrics. 2007. Vol. 119, N 6. P. 1047–1055. doi: 10.1542/peds.2006-2773

[107] Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005;1(2):173–187. doi: 10.5664/jcsm.26314

[108] Meolie A.L., Rosen C., Kristo D., et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence // J Clin Sleep Med. 2005. Vol. 1, N 2. P. 173–187. doi: 10.5664/jcsm.26314

[109] Giambersio D, Marzulli L, Margari L, et al. Correlations between sleep features and iron status in children with neurodevelopmental disorders: A cross-sectional study. J Clin Med. 2023;12(15):4949. doi: 10.3390/jcm12154949

[110] Giambersio D., Marzulli L., Margari L., et al. Correlations between sleep features and iron status in children with neurodevelopmental disorders: A cross-sectional study // J Clin Med. 2023. Vol. 12, N 15. ID 4949. doi: 10.3390/jcm12154949

[111] Torres-Vega A, Pliego-Rivero BF, Otero-Ojeda GA, et al. Limbic system pathologies associated with deficiencies and excesses of the trace elements iron, zinc, copper, and selenium. Nutr Rev. 2012;70(12):679–692. doi: 10.1111/j.1753-4887.2012.00521.x

[112] Torres-Vega A., Pliego-Rivero B.F., Otero-Ojeda G.A., et al. Limbic system pathologies associated with deficiencies and excesses of the trace elements iron, zinc, copper, and selenium // Nutr Rev. 2012. Vol. 70, N 12. P. 679–692. doi: 10.1111/j.1753-4887.2012.00521.x

[113] Maltsev SV. Modern data on vitamin D — metabolism, role in the organism, and features of application in a doctor’s practice. Practicalmedicine. 2020;18(4):8–22. EDN: YTJJFL doi: 10.32000/2072-1757-2020-4-8-22

[114] Мальцев С.В. Современные данные о витамине D — метаболизм, роль в организме, особенности применения в практике врача // Практическая медицина. 2020. Т. 18, № 4. С. 8–22. EDN: YTJJFL doi: 10.32000/2072-1757-2020-4-8-22

[115] Romano F, Muscogiuri G, Di Benedetto E, et al. Vitamin D and sleep regulation: Is there a role for vitamin D? Curr Pharm Des. 2020;26(21):2492–2496. doi: 10.2174/1381612826666200310145935

[116] Romano F., Muscogiuri G., Di Benedetto E., et al. Vitamin D and sleep regulation: Is there a role for vitamin D? // Curr Pharm Des. 2020. Vol. 26, N 21. P. 2492–2496. doi: 10.2174/1381612826666200310145935

[117] Al-Shawwa B, Ehsan Z, Ingram DG. Vitamin D and sleep in children. J Clin Sleep Med. 2020;16(7):1119–1123. doi: 10.5664/jcsm.8440

[118] Al-Shawwa B., Ehsan Z., Ingram D.G. Vitamin D and sleep in children // J Clin Sleep Med. 2020. Vol. 16, N 7. P. 1119–1123. doi: 10.5664/jcsm.8440

[119] Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. 2015;29(6):2207–2222. doi: 10.1096/fj.14-268342

[120] Patrick R.P., Ames B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior // FASEB J. 2015. Vol. 29, N 6. P. 2207–2222. doi: 10.1096/fj.14-268342

[121] Abboud M. Vitamin D supplementation and sleep: A systematic review and meta-analysis of intervention studies. Nutrients. 2022;14(5):1076. doi: 10.3390/nu14051076

[122] Abboud M. Vitamin D supplementation and sleep: A systematic review and meta-analysis of intervention studies // Nutrients. 2022. Vol. 14, N 5. ID 1076. doi: 10.3390/nu14051076

RIGHTS & PERMISSIONS

ECO-vector LLC